SS
CRVS icon

SBI Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

SBI Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Buy
11,364
+10,360
+1,032% +$144K ﹤0.01% 717
2026
Q1 		$14.7K Hold
1,004
– – ﹤0.01% 1582
2025
Q4 		$7.73K Sell
1,004
-2
-0.2% -$16 ﹤0.01% 1835
2025
Q3 		$7.41K Buy
1,006
+6
+0.6% +$31 ﹤0.01% 1892
2025
Q2 		$4K Hold
1,000
– – ﹤0.01% 2094
2025
Q1 		$3.18K Hold
1,000
– – ﹤0.01% 2080
2024
Q4 		$5.35K Buy
+1,000
New +$7.46K ﹤0.01% 1902

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SBI Securities's CRVS Position: Q2 2026 in Review

SBI Securities increased its Corvus Pharmaceuticals (CRVS) stake by 1,032% in Q2 2026, buying an estimated $144K and bringing the position to 11,364 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

SBI Securities first reported a position in CRVS in Q4 2024 and has held it in 7 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • SBI Securities held 11,364 shares of Corvus Pharmaceuticals worth $170K as of Q2 2026.
  • SBI Securities bought 10,360 Corvus Pharmaceuticals shares in Q2 2026, an estimated $144K.
  • Corvus Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #717 holding.
  • SBI Securities first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.